TY - JOUR
T1 - Mcr-1 expression in progression of colistin resistance gram negative bacilli of clinical specimens derived from Intensive Care Units, wards and hospital setting of Deccan Eco Region of Southern India
AU - Reddy, B. Rama Chandra
AU - Geetha, R. V.
AU - Singh, Manisha
AU - Rani, Ramavath Usha
AU - Nekkanti, Kasvi Nagaja
N1 - Funding Information:
The authors thankful to clinicians and technicians who support in clinical material collection and sample analysis.
Publisher Copyright:
© 2022 Wolters Kluwer Medknow Publications. All rights reserved.
PY - 2022
Y1 - 2022
N2 - The involvement of the "mcr-1" gene in the transmission of this colistin-resistant gram-negative bacteria (GNB) poses a serious threat to current clinical management of human community acquired infections. Current study aim is to determine the prevalence of colistin resistance clinical isolates obtained from patients of ICUs, wards of a tertiary hospital, and to detect the ‘mcr-1’ gene using real-time PCR assay. A total of 2032 different clinical specimens were processed at Microbiology laboratory. From these, 1852 gram-negative isolates further processed for antimicrobial susceptibility test for Colistin resistance through minimum inhibitory VITEK method. Colistin resistant strains were further screened for mcr-1 gene using polymerase chain reaction (PCR). Among the total clinical samples, 91.14% isolates were Gram-negative bacilli. The most predominant isolate among Gram-negatives was K. pneumonia, and E. coli. 20% of E. coli and 25% of K. pneumonia were resistant to carbapenem. From the 1853 GNB isolates, 31 colistin resistance isolates were identified. Among 31 colistin resistant GNB, 41.94% (13/31) were Klebsiella sps, 25.81% (8/31) were E.coli, 19.36 % (6/31) were Pseudomonas sps, 6.45 %(2/31) were Acinetobacter Sps, and 6.45% (2/31) were Enterobacter species respectively. In MIC assay, majority of E. coli and K. pneumonia confirmed as colistin resistant at MIC≥4 µg/ml. K. pneumoniae had a higher prevalence of colistin resistance than compared to E. coli (0.71%vs 0.42%, p<0.05). Overall, the prevalence of colistin resistance was 1.637% (31/1852) and the acquisition rate of ‘mcr-1’ was 6.45% (2/31). Resistance to drug colistin and its isolation of mcr-1 indicate further emergency in infection management. Hence, extensive surveillance, formulation and implementation of effective strategies, and extension of diagnostic facilities can be some remedies to cope with this global crisis.
AB - The involvement of the "mcr-1" gene in the transmission of this colistin-resistant gram-negative bacteria (GNB) poses a serious threat to current clinical management of human community acquired infections. Current study aim is to determine the prevalence of colistin resistance clinical isolates obtained from patients of ICUs, wards of a tertiary hospital, and to detect the ‘mcr-1’ gene using real-time PCR assay. A total of 2032 different clinical specimens were processed at Microbiology laboratory. From these, 1852 gram-negative isolates further processed for antimicrobial susceptibility test for Colistin resistance through minimum inhibitory VITEK method. Colistin resistant strains were further screened for mcr-1 gene using polymerase chain reaction (PCR). Among the total clinical samples, 91.14% isolates were Gram-negative bacilli. The most predominant isolate among Gram-negatives was K. pneumonia, and E. coli. 20% of E. coli and 25% of K. pneumonia were resistant to carbapenem. From the 1853 GNB isolates, 31 colistin resistance isolates were identified. Among 31 colistin resistant GNB, 41.94% (13/31) were Klebsiella sps, 25.81% (8/31) were E.coli, 19.36 % (6/31) were Pseudomonas sps, 6.45 %(2/31) were Acinetobacter Sps, and 6.45% (2/31) were Enterobacter species respectively. In MIC assay, majority of E. coli and K. pneumonia confirmed as colistin resistant at MIC≥4 µg/ml. K. pneumoniae had a higher prevalence of colistin resistance than compared to E. coli (0.71%vs 0.42%, p<0.05). Overall, the prevalence of colistin resistance was 1.637% (31/1852) and the acquisition rate of ‘mcr-1’ was 6.45% (2/31). Resistance to drug colistin and its isolation of mcr-1 indicate further emergency in infection management. Hence, extensive surveillance, formulation and implementation of effective strategies, and extension of diagnostic facilities can be some remedies to cope with this global crisis.
KW - Colistin
KW - E. coli
KW - PCR assay
KW - VITEK
KW - mcr-1
UR - http://www.scopus.com/inward/record.url?scp=85143363454&partnerID=8YFLogxK
U2 - 10.47750/pnr.2022.13.S07.040
DO - 10.47750/pnr.2022.13.S07.040
M3 - Article
AN - SCOPUS:85143363454
SN - 0976-9234
VL - 13
SP - 295
EP - 305
JO - Journal of Pharmaceutical Negative Results
JF - Journal of Pharmaceutical Negative Results
ER -